Use of simian immunodeficiency virus for vaccine research.
Rhesus monkeys were immunized with purified, disrupted, noninfectious simian immunodeficiency virus (SIV) in adjuvant induced SIV neutralizing antibodies. Two of six previously vaccinated macaques were protected against infection when challenged with 200-1,000 animal infectious doses of uncloned, pathogenic SIV and both have remained free of signs of virus infection for 19 and 30 months. Prior vaccination appeared to be of benefit in decreasing the virus load and in delaying the onset of AIDS in animals that became infected. Nonetheless, two of four previously vaccinated monkeys that became infected following challenge eventually developed AIDS and died 505 and 538 days after infection. Thus, for a vaccine to be truly effective against AIDS, it may have to protect absolutely against initial infection.
Daniel
M D
MD
New England Regional Primate Research Center, Harvard Medical School, Southborough, MA.
Sehgal
P K
PK
Kodama
T
T
Wyand
M S
MS
Ringler
D J
DJ
King
N W
NW
Schmidt
D K
DK
Troup
C D
CD
Desrosiers
R C
RC
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D008253:Macaca mulatta; D009500:Neutralization Tests; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D015996:Survival Rate; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014765:Viral Vaccines